Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.52 |
| ▸ | MAPK3 | P27361 | 10/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.46 |
| ▸ | FGFR4 | P22455 | 4/20 | 0.46 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.46 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.46 |
| ▸ | PLK1 | P53350 | 1/20 | 0.43 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.43 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.43 |
| ▸ | TTK | P33981 | 1/20 | 0.43 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23606836 | 1.00 | EGFR (0.52) | EGFRMAPK3JAK3FGFR1FGFR4 | |
| SCHEMBL23606862 | 0.95 | EGFR (0.54) | EGFRMAPK3JAK3FGFR1FGFR4 | |
| SCHEMBL30045116 | 0.95 | EGFR (0.54) | EGFRMAPK3JAK3FGFR1FGFR4 | |
| SCHEMBL30045153 | 0.92 | MAPK3 (0.50) | EGFRMAPK3JAK3FGFR1FGFR4 | |
| SCHEMBL23606369 | 0.92 | MAPK3 (0.50) | EGFRMAPK3JAK3FGFR1FGFR4 | |
| SCHEMBL23606781 | 0.91 | MAPK3 (0.52) | EGFRMAPK3JAK3FGFR1FGFR4 | |
| SCHEMBL30044388 | 0.91 | JAK3 (0.49) | EGFRMAPK3JAK3FGFR1FGFR4 | |
| SCHEMBL23606783 | 0.91 | JAK3 (0.49) | EGFRMAPK3JAK3FGFR1FGFR4 | |
| SCHEMBL30044249 | 0.91 | MAPK3 (0.52) | EGFRMAPK3JAK3FGFR1FGFR4 | |
| SCHEMBL25140070 | 0.89 | JAK3 (0.54) | EGFRMAPK3JAK3FGFR1FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12582654-B2 | Cyano-substituted pyridine and cyano-substituted pyrimidine compound and preparation method therefor and application thereof | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2026-03-24 | — | — | US | disclosed |
| EP-4083021-B1 | CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2025-07-02 | — | — | EP | disclosed |
| US-20230125046-A1 | CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2023-04-20 | — | — | US | disclosed |
| EP-4083021-A1 | CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2022-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230125046-A1 | CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | FGFR4, FGFR1, WEE1 | EGFR 561/4885MAPK3 809/4885JAK3 372/4885 |
| US-12582654-B2 | Cyano-substituted pyridine and cyano-substituted pyrimidine compound and preparation method therefor and application thereof | FGFR4, FGFR3, FGFR1 | EGFR 60/4885MAPK3 446/4885JAK3 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.